Vincenza Andrisano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9286385/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	\hat{l}^2 -Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochemical Pharmacology, 2003, 65, 407-416.	2.0	518
2	Insight Into the Kinetic of Amyloid β (1–42) Peptide Selfâ€Aggregation: Elucidation of Inhibitors' Mechanism of Action. ChemBioChem, 2007, 8, 2152-2161.	1.3	328
3	3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy§. Journal of Medicinal Chemistry, 2003, 46, 2279-2282.	2.9	259
4	Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer's Disease. Journal of Medicinal Chemistry, 2007, 50, 6446-6449.	2.9	244
5	Rational Approach To Discover Multipotent Anti-Alzheimer Drugs. Journal of Medicinal Chemistry, 2005, 48, 360-363.	2.9	225
6	Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors:  New Disease-Modifying Agents for Alzheimer's Disease. Journal of Medicinal Chemistry, 2005, 48, 7223-7233.	2.9	203
7	Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 423-426.	1.0	197
8	Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation. Journal of Medicinal Chemistry, 2008, 51, 3588-3598.	2.9	186
9	Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush. Journal of Medicinal Chemistry, 2008, 51, 4381-4384.	2.9	184
10	Benzofuran-Based Hybrid Compounds for the Inhibition of Cholinesterase Activity, β Amyloid Aggregation, and Aβ Neurotoxicity. Journal of Medicinal Chemistry, 2008, 51, 2883-2886.	2.9	181
11	A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease. Angewandte Chemie - International Edition, 2007, 46, 3689-3692.	7.2	172
12	Pyrano[3,2- <i>c</i>]quinolineâ^'6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds. Journal of Medicinal Chemistry, 2009, 52, 5365-5379.	2.9	164
13	SAR of 9-Amino-1,2,3,4-tetrahydroacridine-Based Acetylcholinesterase Inhibitors:Â Synthesis, Enzyme Inhibitory Activity, QSAR, and Structure-Based CoMFA of Tacrine Analogues. Journal of Medicinal Chemistry, 2000, 43, 2007-2018.	2.9	142
14	Multitarget Drug Design Strategy: Quinone–Tacrine Hybrids Designed To Block Amyloid-β Aggregation and To Exert Anticholinesterase and Antioxidant Effects. Journal of Medicinal Chemistry, 2014, 57, 8576-8589.	2.9	139
15	Propidium-Based Polyamine Ligands as Potent Inhibitors of Acetylcholinesterase and Acetylcholinesterase-Induced Amyloid-Î ² Aggregation. Journal of Medicinal Chemistry, 2005, 48, 24-27.	2.9	137
16	Tacripyrines, the First Tacrineâ^'Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2009, 52, 2724-2732.	2.9	134
17	Synthesis and Multitarget Biological Profiling of a Novel Family of Rhein Derivatives As Disease-Modifying Anti-Alzheimer Agents. Journal of Medicinal Chemistry, 2014, 57, 2549-2567.	2.9	132
18	Design, Synthesis, and Biological Evaluation of Conformationally Restricted Rivastigmine Analogues. Journal of Medicinal Chemistry, 2004, 47, 5945-5952.	2.9	129

#	Article	IF	CITATIONS
19	Novel Class of Quinone-Bearing Polyamines as Multi-Target-Directed Ligands To Combat Alzheimer's Disease. Journal of Medicinal Chemistry, 2007, 50, 4882-4897.	2.9	125
20	Strategies for the Inhibition of Protein Aggregation in Human Diseases. ChemBioChem, 2010, 11, 1018-1035.	1.3	120
21	Novel Tacrine–Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography. Journal of Medicinal Chemistry, 2016, 59, 114-131.	2.9	111
22	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACEâ€1 and GSKâ€3β Inhibitors. Angewandte Chemie - International Edition, 2015, 54, 1578-1582.	7.2	107
23	Kinetic characterization of amyloid-beta 1–42 aggregation with a multimethodological approach. Analytical Biochemistry, 2011, 414, 215-225.	1.1	103
24	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3Î ² Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 531-544.	2.9	100
25	Huprine–Tacrine Heterodimers as Anti-Amyloidogenic Compounds of Potential Interest against Alzheimer's and Prion Diseases. Journal of Medicinal Chemistry, 2012, 55, 661-669.	2.9	90
26	Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorganic and Medicinal Chemistry, 2010, 18, 1749-1760.	1.4	89
27	Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11 H -indeno-[1,2- b]-quinolin-10-ylamine derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 497-506.	1.4	88
28	Cholinesterase Inhibitors:Â Xanthostigmine Derivatives Blocking the Acetylcholinesterase-Induced β-Amyloid Aggregation. Journal of Medicinal Chemistry, 2005, 48, 4444-4456.	2.9	86
29	Amyloid β-Peptide 25–35 Self-Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer's Disease Process and Treatment. ACS Chemical Neuroscience, 2012, 3, 952-962.	1.7	85
30	Drug affinity to immobilized target bio-polymers by high-performance liquid chromatography and capillary electrophoresis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 797, 111-129.	1.2	84
31	Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Analytical and Bioanalytical Chemistry, 2011, 400, 1979-1996.	1.9	82
32	Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. European Journal of Medicinal Chemistry, 2016, 108, 687-700.	2.6	82
33	Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. European Journal of Medicinal Chemistry, 2011, 46, 5435-5442.	2.6	81
34	Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone for Potential Use against Alzheimer's Disease. Journal of Medicinal Chemistry, 1998, 41, 4186-4189.	2.9	80
35	Extensive SAR and Computational Studies of 3-{4-[(Benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2 <i>H</i> -2-chromenone (AP2238) Derivatives. Journal of Medicinal Chemistry, 2007, 50, 4250-4254.	2.9	78
36	Cystamine-tacrine dimer: A new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Neuropharmacology, 2012, 62, 997-1003.	2.0	77

#	Article	IF	CITATIONS
37	MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond. Current Pharmaceutical Design, 2009, 15, 601-613.	0.9	75
38	Monolithic micro-immobilized-enzyme reactor with human recombinant acetylcholinesterase for on-line inhibition studies. Journal of Chromatography A, 2004, 1031, 27-34.	1.8	74
39	Acetylcholinesterase Inhibitors:  Synthesis and Structureâ^'Activity Relationships of ω-[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl Derivatives. Journal of Medicinal Chemistry, 1998, 41, 3976-3986.	2.9	73
40	Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chemico-Biological Interactions, 2010, 187, 411-415.	1.7	71
41	Toward a Rational Design of Multitarget-Directed Antioxidants: Merging Memoquin and Lipoic Acid Molecular Frameworks. Journal of Medicinal Chemistry, 2009, 52, 7883-7886.	2.9	69
42	Novel 8â€Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer′s Disease. ChemMedChem, 2016, 11, 1284-1295.	1.6	69
43	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. Journal of Medicinal Chemistry, 2016, 59, 6387-6406.	2.9	66
44	Acetylcholinesterase Inhibitors:Â SAR and Kinetic Studies on ï‰-[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl Derivatives. Journal of Medicinal Chemistry, 2001, 44, 3810-3820.	2.9	65
45	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[ï‰-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorganic and Medicinal Chemistry, 2007, 15, 575-585.	1.4	65
46	Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2655-2658.	1.0	62
47	Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. European Journal of Medicinal Chemistry, 2012, 52, 251-262.	2.6	62
48	Novel Tacrineâ€Grafted Ugi Adducts as Multipotent Antiâ€Alzheimer Drugs: A Synthetic Renewal in Tacrine–Ferulic Acid Hybrids. ChemMedChem, 2015, 10, 523-539.	1.6	62
49	Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor. Journal of Chromatography A, 2007, 1144, 102-110.	1.8	60
50	Structureâ^'Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 4. Further Investigation on the Inner Spacer. Journal of Medicinal Chemistry, 2008, 51, 7308-7312.	2.9	56
51	Novel Huprine Derivatives with Inhibitory Activity toward βâ€Amyloid Aggregation and Formation as Diseaseâ€Modifying Antiâ€Alzheimer Drug Candidates. ChemMedChem, 2010, 5, 1855-1870.	1.6	56
52	2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. European Journal of Medicinal Chemistry, 2012, 58, 519-532.	2.6	56
53	3,4-Dihydro-1,3,5-triazin-2(1 <i>H</i>)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. ACS Chemical Neuroscience, 2015, 6, 1665-1682.	1.7	54
54	Ubiquitous Amyloids. Applied Biochemistry and Biotechnology, 2012, 166, 1626-1643.	1.4	51

#	Article	IF	CITATIONS
55	Diseaseâ€Modifying Antiâ€Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with <i>β</i> â€Amyloid Aggregation. CNS Neuroscience and Therapeutics, 2014, 20, 624-632.	1.9	51
56	UHPLC determination of catechins for the quality control of green tea. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 307-314.	1.4	50
57	Choosing the right chromatographic support in making a new acetylcholinesterase-micro-immobilised enzyme reactor for drug discovery. Journal of Chromatography A, 2005, 1065, 135-144.	1.8	49
58	Optimization of a trypsin-bioreactor coupled with high-performance liquid chromatography–electrospray ionization tandem mass spectrometry for quality control of biotechnological drugs. Journal of Chromatography A, 2006, 1120, 121-131.	1.8	49
59	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. ACS Medicinal Chemistry Letters, 2013, 4, 225-229.	1.3	48
60	Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Analytical and Bioanalytical Chemistry, 2007, 388, 1175-1183.	1.9	47
61	Protein Flexibility in Virtual Screening: The BACE-1 Case Study. Journal of Chemical Information and Modeling, 2012, 52, 2697-2704.	2.5	47
62	Reliable assay of extreme enantiomeric purity values by a new circular dichroism based HPLC detection system. , 2000, 12, 84-92.		46
63	Protective Effects of Cyanidin-3-O-β-glucopyranoside Against UVA-induced Oxidative Stress in Human Keratinocytes¶. Photochemistry and Photobiology, 2005, 81, 623.	1.3	46
64	Development of immobilized enzyme reactors based on human recombinant cytochrome P450 enzymes for phase I drug metabolism studies. Journal of Chromatography A, 2008, 1206, 2-10.	1.8	46
65	Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues. European Journal of Medicinal Chemistry, 2011, 46, 6119-6130.	2.6	46
66	Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?. Journal of Medicinal Chemistry, 2021, 64, 26-41.	2.9	46
67	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. Journal of Medicinal Chemistry, 2021, 64, 812-839.	2.9	45
68	Enantioselective Extraction of Dinitrophenyl Amino Acids Mediated by Lipophilic Deoxyguanosine Derivatives: Chiral Discrimination by Self-Assembly. Angewandte Chemie - International Edition, 1999, 38, 2386-2388.	7.2	44
69	From the dual function lead AP2238 to AP2469, a multiâ€ŧargetâ€directed ligand for the treatment of Alzheimer's disease. Pharmacology Research and Perspectives, 2014, 2, e00023.	1.1	44
70	Benzophenone-based derivatives: A novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. European Journal of Medicinal Chemistry, 2011, 46, 1682-1693.	2.6	43
71	Amaryllidaceae alkaloids from Narcissus pseudonarcissus L. cv. Dutch Master as potential drugs in treatment of Alzheimer's disease. Phytochemistry, 2019, 165, 112055.	1.4	43
72	Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§. Current Medicinal Chemistry, 2017, 24, 3522-3546.	1.2	43

#	Article	IF	CITATIONS
73	Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation. ACS Medicinal Chemistry Letters, 2013, 4, 1178-1182.	1.3	40
74	Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein–huprine hybrids. Future Medicinal Chemistry, 2017, 9, 965-981.	1.1	40
75	Development and characterization of an immobilized enzyme reactor based on glyceraldehyde-3-phosphate dehydrogenase for on-line enzymatic studies. Journal of Chromatography A, 2003, 987, 331-340.	1.8	39
76	Bis(7)â€ŧacrine Derivatives as Multitargetâ€Directed Ligands: Focus on Anticholinesterase and Antiamyloid Activities. ChemMedChem, 2010, 5, 1215-1220.	1.6	39
77	1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: Synthesis, pharmacological evaluation and mechanistic studies. European Journal of Medicinal Chemistry, 2014, 73, 141-152.	2.6	39
78	The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?. ACS Medicinal Chemistry Letters, 2012, 3, 182-186.	1.3	38
79	Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease. Journal of Chromatography A, 2009, 1216, 2730-2738.	1.8	37
80	Multi-target strategy to address Alzheimer's disease: Design, synthesis and biological evaluation of new tacrine-based dimers. European Journal of Medicinal Chemistry, 2011, 46, 4336-4343.	2.6	37
81	Structureâ^'Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 2. Role of the Substituents on the Phenyl Ring and Nitrogen Atoms of Caproctamine. Journal of Medicinal Chemistry, 2003, 46, 954-966.	2.9	35
82	LC–MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products. Journal of Pharmaceutical and Biomedical Analysis, 2014, 91, 185-192.	1.4	35
83	Studies on the photostability and in vitro phototoxicity of Labetalol. European Journal of Pharmaceutical Sciences, 2001, 12, 495-504.	1.9	34
84	Methotrexate determination in pharmaceuticals by enantioselective HPLC. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 919-925.	1.4	33
85	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets. Fìtoterapìâ, 2016, 109, 241-247.	1.1	33
86	Structureâ^'Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 3. Effect of Replacing the Inner Polymethylene Chain with Cyclic Moieties. Journal of Medicinal Chemistry, 2004, 47, 6490-6498.	2.9	32
87	New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation. European Journal of Medicinal Chemistry, 2017, 141, 197-210.	2.6	32
88	Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2019, 10, 469-474.	1.3	32
89	Natureâ€Inspired Multifunctional Ligands: Focusing on Amyloidâ€Based Molecular Mechanisms of Alzheimer's Disease. ChemMedChem, 2016, 11, 1309-1317.	1.6	31
90	A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017. Expert Opinion on Therapeutic Patents, 2018, 28, 455-465.	2.4	31

#	Article	IF	CITATIONS
91	Acetylcholinesterase inhibition by tacrine analogues. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 2599-2602.	1.0	30
92	Development and characterization of Î ² -secretase monolithic micro-immobilized enzyme reactor for on-line high-performance liquid chromatography studies. Journal of Chromatography A, 2007, 1175, 217-226.	1.8	30
93	Mechanism and stereoselectivity of HDAC I inhibition by (R)-9-hydroxystearic acid in colon cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 1334-1340.	1.2	30
94	The Bivalent Ligand Approach as a Tool for Improving the in vitro Antiâ€Alzheimer Multitarget Profile of Dimebon. ChemMedChem, 2013, 8, 1276-1281.	1.6	30
95	Design, synthesis, in silico and in vitro screening of 1,2,4-thiadiazole analogues as non-peptide inhibitors of beta-secretase. Bioorganic Chemistry, 2014, 57, 90-98.	2.0	30
96	Hexahydrochromeno[4,3-b]pyrrole Derivatives as Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2001, 44, 105-109.	2.9	29
97	Synthesis of Monomeric Derivatives To Probe Memoquin's Bivalent Interactions. Journal of Medicinal Chemistry, 2011, 54, 8299-8304.	2.9	27
98	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2012, 48, 206-213.	2.6	27
99	From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2804-2808.	1.0	27
100	Immobilized Enzyme Reactors: an Overview of Applications in Drug Discovery from 2008 to 2018. Chromatographia, 2019, 82, 425-441.	0.7	27
101	Structure–Activity Relationships and Binding Mode in the Human Acetylcholinesterase Active Site of Pseudoâ€Irreversible Inhibitors Related to Xanthostigmine. ChemMedChem, 2009, 4, 670-679.	1.6	26
102	A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. European Journal of Medicinal Chemistry, 2019, 180, 613-626.	2.6	26
103	Determination of the chiral and achiral related substances of methotrexate by cyclodextrin-modified micellar electrokinetic chromatography. Electrophoresis, 2004, 25, 2830-2837.	1.3	25
104	Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry. Journal of Chromatography A, 2006, 1129, 73-81.	1.8	25
105	Histone postâ€ŧranslational modifications by HPLCâ€ESlâ€MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics, 2009, 9, 5437-5445.	1.3	25
106	Structure–activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4312-4315.	1.0	25
107	Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. Journal of Medicinal Chemistry, 2020, 63, 9360-9390.	2.9	25
108	Determination of the dissociation constants (pKa) of basic acetylcholinesterase inhibitors by reversed-phase liquid chromatography. Journal of Chromatography A, 2002, 958, 59-67.	1.8	24

#	Article	IF	CITATIONS
109	Analytical methods for the determination of folic acid in a polymeric micellar carrier. Journal of Pharmaceutical and Biomedical Analysis, 2003, 32, 983-989.	1.4	24
110	Chemical and Pharmacological Studies on Enantiomerically Pure <i>p</i> â€Methoxytacripyrines, Promising Multiâ€Targetâ€Directed Ligands for the Treatment of Alzheimer's Disease. ChemMedChem, 2011, 6, 1990-1997.	1.6	24
111	Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3Î ² Inhibitors. Molecules, 2018, 23, 719.	1.7	24
112	Analytical study of penicillamine in pharmaceuticals by capillary zone electrophoresis. Journal of Chromatography A, 1999, 844, 361-369.	1.8	21
113	Fluorinated benzophenone derivatives: Balanced multipotent agents for Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 78, 157-166.	2.6	21
114	Determination of levamisole and tetramisole in seized cocaine samples by enantioselective high-performance liquid chromatography and circular dichroism detection. Journal of Chromatography A, 2014, 1363, 150-154.	1.8	21
115	Hydroxy-substituted trans -cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 139, 378-389.	2.6	21
116	(±)- BIGI-3h : Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease. ACS Chemical Neuroscience, 2021, 12, 1328-1342.	1.7	21
117	Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarinâ€Based Derivatives. ChemMedChem, 2016, 11, 1296-1308.	1.6	20
118	Study of donepezil binding to serum albumin by capillary electrophoresis and circular dichroism. Analytical and Bioanalytical Chemistry, 2003, 377, 875-879.	1.9	19
119	Development of a liquid chromatographic system with fluorescent detection for β-secretase immobilized enzyme reactor on-line enzymatic studies. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 355-361.	1.4	19
120	Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6254-6258.	1.0	19
121	Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy. Molecules, 2016, 21, 400.	1.7	19
122	Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-l² aggregation. Future Medicinal Chemistry, 2017, 9, 953-963.	1.1	19
123	Investigating in Vitro Amyloid Peptide 1–42 Aggregation: Impact of Higher Molecular Weight Stable Adducts. ACS Omega, 2019, 4, 12308-12318.	1.6	19
124	Heterocyclic inhibitors of AChE acylation and peripheral sites. Il Farmaco, 2005, 60, 465-473.	0.9	18
125	The role of Li ⁺ , Na ⁺ , and K ⁺ in the ligand binding inside the human acetylcholinesterase gorge. Proteins: Structure, Function and Bioinformatics, 2008, 70, 779-785.	1.5	17
126	Disclosure of a fundamental clue for the elucidation of the myricetin mechanism of action as amyloid aggregation inhibitor by mass spectrometry. Electrophoresis, 2012, 33, 3380-3386.	1.3	17

#	Article	IF	CITATIONS
127	Surface plasmon resonance, fluorescence, and circular dichroism studies for the characterization of the binding of BACE-1 inhibitors. Analytical and Bioanalytical Chemistry, 2013, 405, 827-835.	1.9	17
128	Advanced analytical methodologies in Alzheimer's disease drug discovery. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112899.	1.4	17
129	VASOACTIVE COCKTAILS FOR ERECTILE DYSFUNCTION: CHEMICAL STABILITY OF PGE1, PARAVERINE AND PHENTOLAMINE. Journal of Urology, 1998, 160, 551-555.	0.2	16
130	Polyamine Conjugation as a Promising Strategy To Target Amyloid Aggregation in the Framework of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2016, 7, 1145-1150.	1.3	16
131	Sequential Virtual Screening Approach to the Identification of Small Organic Molecules as Potential BACEâ€∎ Inhibitors. Chemical Biology and Drug Design, 2011, 77, 268-271.	1.5	15
132	Determination of dextromethorphan and levomethorphan in seized heroin samples by enantioselective HPLC and electronic CD. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 76-79.	1.4	15
133	Multi-target neuroprotective effects of herbal medicines for Alzheimer's disease. Journal of Ethnopharmacology, 2022, 290, 115107.	2.0	15
134	Determination of glutathione in biological samples by high performance liquid chromatography with fluorescence detection. Biomedical Chromatography, 1994, 8, 306-308.	0.8	14
135	Human recombinant beta-secretase immobilized enzyme reactor for fast hits' selection and characterization from a virtual screening library. Journal of Pharmaceutical and Biomedical Analysis, 2013, 73, 131-134.	1.4	14
136	Concise Enantioselective Synthesis and Attribution of the Absolute Configuration of Two-Carbon Bridge Methoxylated Cocaines and Pseudococaines. Journal of Organic Chemistry, 1998, 63, 4834-4837.	1.7	12
137	Analysis of human histone H4 by capillary electrophoresis in a pullulan-coated capillary, LC-ESI-MS and MALDI-TOF-MS. Analytical and Bioanalytical Chemistry, 2008, 390, 1881-1888.	1.9	12
138	Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks. ACS Medicinal Chemistry Letters, 2019, 10, 1407-1414.	1.3	12
139	Stereoselectivity at ?-adrenoreceptor subtypes: observations with the enantiomers of WB 4101 separated through their amides ofN-Tosyl-(S)-proline. Chirality, 1992, 4, 16-20.	1.3	10
140	Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. Il Farmaco, 2003, 58, 917-928.	0.9	10
141	The rapid and direct determination of ATPase activity by ion exchange chromatography and the application to the activity of heat shock protein-90. Journal of Pharmaceutical and Biomedical Analysis, 2013, 73, 77-81.	1.4	10
142	Liquid chromatographic enzymatic studies with on-line Beta-secretase immobilized enzyme reactor and 4-(4-dimethylaminophenylazo) benzoic acid/5-[(2-aminoethyl) amino] naphthalene-1-sulfonic acid peptide as fluorogenic substrate. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 953-954, 108-114.	1.2	10
143	Analysis of prostaglandin E1 and related impurities by mixed aqueous-organic capillary electrophoresis. Journal of Separation Science, 2001, 24, 749-756.	1.3	9
144	Thermal and catalytic reactions of ethyl diazopyruvate with [60]fullerene. Tetrahedron, 2010, 66, 7329-7332.	1.0	9

#	Article	IF	CITATIONS
145	Unusual reaction of 1,4-diamino-2-nitrobenzene derivatives toward nucleophiles: Catalysis by sodium sulphite. Tetrahedron, 1998, 54, 4647-4654.	1.0	8
146	Batchwise covalent immobilization of human acetylcholinesterase: Kinetic and inhibition spectrophotometric studies. Analytical Biochemistry, 2005, 342, 163-166.	1.1	8
147	Design, synthesis, and biological evaluation of substituted 2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamine related compounds as fructose-1,6-bisphosphatase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 7846-7853.	1.4	8
148	Stereoselective determination of allethrin by two-dimensional achiral/chiral liquid chromatography with ultraviolet/circular dichroism detection. Journal of Chromatography A, 2004, 1046, 67-73.	1.8	8
149	Pig liver esterase (PLE)-mediated resolution of N-substituted 4-benzoyloxy-3-carbomethoxypiperidines: a convenient preparation of 4-hydroxy- and 4-benzoyloxy-3-carbomethoxypiperidines in enantiomerically pure form. Tetrahedron: Asymmetry, 2000, 11, 4397-4405.	1.8	7
150	Analysis of guaifenesin-based cough syrups by micellar electrokinetic chromatography and GC-MS. Journal of Separation Science, 2001, 24, 258-264.	1.3	7
151	Liquid chromatography–tandem mass spectrometry for the identification of impurities in d-allethrin samples. Journal of Chromatography A, 2005, 1099, 149-156.	1.8	7
152	Application of an ESI-QTOF method for the detailed characterization of GSK-3β inhibitors. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 159-166.	1.4	7
153	Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth. Molecules, 2020, 25, 4438.	1.7	7
154	From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. European Journal of Medicinal Chemistry, 2021, 225, 113779.	2.6	7
155	Monoterpene indole alkaloids from Vinca minor L. (Apocynaceae): Identification of new structural scaffold for treatment of Alzheimer's disease. Phytochemistry, 2022, 194, 113017.	1.4	7
156	Two-carbon bridge substituted cocaines: enantioselective synthesis, attribution of the absolute configuration and biological activity of novel 6- and 7-methoxylated cocaines. Il Farmaco, 1999, 54, 275-287.	0.9	6
157	Investigation of the photochemical properties and in vitro phototoxic potential of bumetanide. Photochemical and Photobiological Sciences, 2003, 2, 1011.	1.6	6
158	GC-FID/MS method for the impurity profiling of synthetic d-allethrin. Journal of Separation Science, 2004, 27, 89-95.	1.3	6
159	Separation and quantitation of fructose-6-phosphate and fructose-1,6-diphosphate by LC-ESI-MS for the evaluation of fructose-1,6-biphosphatase activity. Journal of Separation Science, 2006, 29, 2395-2400.	1.3	6
160	Site-specific quantification of lysine acetylation in the N-terminal tail of histone H4 using a double-labelling, targeted UHPLC MS/MS approach. Analytical and Bioanalytical Chemistry, 2016, 408, 3547-3553.	1.9	6
161	Synthesis and partition profiles of nicotinic acid derivatives with oligomeric carriers. Journal of Controlled Release, 1986, 3, 185-191.	4.8	5
162	Monolithic stationary phase coupled with coulometric detection: Development of an ionâ€pair HPLC method for the analysis of quinoneâ€bearing compounds. Journal of Separation Science, 2007, 30, 2935-2942.	1.3	5

#	Article	IF	CITATIONS
163	Investigation of the photostability properties of memoquin, a quinone derivative for the treatment of Alzheimer's disease. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 164-170.	1.4	5
164	Mass Spectrometry as an Efficient Tool for the Characterization of Amyloid β Peptide 25–35 Self-Assembly Species in Aggregation and Inhibition Studies. European Journal of Mass Spectrometry, 2013, 19, 483-490.	0.5	5
165	Structural characterization of p53 isoforms due to the polymorphism at codon 72 by mass spectrometry and circular dichroism. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 200-206.	1.4	3
166	Fluorescence biosensing micropatterned surfaces based on immobilized human acetylcholinesterase. Analytical and Bioanalytical Chemistry, 2013, 405, 795-804.	1.9	3
167	[4-[[N -(3-Chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors. Bioorganic and Medicinal Chemistry, 2000, 8, 681-689.	1.4	2
168	Simultaneous separation and determination of Tarabine PFS and Adriblastine using micellar electrokinetic chromatography and high performance liquid chromatography. Application to some biological fluids. Journal of Separation Science, 2005, 28, 534-542.	1.3	2
169	LC Analysis of Oxytetracycline and Chlortetracycline: Application for In Vitro Bio-Equivalence Study of Veterinary Medicines. Chromatographia, 2009, 69, 215-220.	0.7	2
170	Reprint of: Liquid chromatographic enzymatic studies with on-line Beta-secretase immobilized enzyme reactor and 4-(4-dimethylaminophenylazo) benzoic acid/5-[(2-aminoethyl) amino] naphthalene-1-sulfonic acid peptide as fluorogenic substrate. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 968, 94-100.	1.2	2
171	Direct determination of GSK-3β activity and inhibition by UHPLC-UV–vis diode arrays detector (DAD). Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 104-111.	1.4	2
172	Bio-Guided Fractionation of Stem Bark Extracts from Phyllanthus muellarianus: Identification of Phytocomponents with Anti-Cholinesterase Activity. Molecules, 2021, 26, 4376.	1.7	2
173	Self-assembly of biomolecules: AFM study of F-actin on unstructured and nanostructured surfaces. , 2009, , .		1
174	Natural products as novel scaffolds for the design of glycogen synthase kinase 3β inhibitors. Expert Opinion on Drug Discovery, 2022, 17, 377-396.	2.5	1
175	Aβ1-42 peptide toxicity on neuronal cells: A lipidomic study. Journal of Pharmaceutical and Biomedical Analysis, 2022, 219, 114876.	1.4	1
176	Design, Synthesis and Biological Evaluation of Ambenonium Derivatives as AChE Inhibitors ChemInform, 2004, 35, no.	0.1	0
177	AFM study of F-actin on chemically modified surfaces. , 2010, , .		0